Analysis of 1 case of liver damage caused by tigecycline
Tigecycline is a new broad-spectrum antibacterial drug,which has ultra-broad-spectrum antibacterial activity,and is listed in China in December 2011.Its mechanism is very similar to tetracycline,and it is not easy to produce resistance.Tigecycline has a wide range of bacteriostatic activity and exerts significant bacteriostatic effects in a variety of diseases,but with the misuse of antibiotics,it has led to the reappearance of multidrug-resistant bacteria,and the most common adverse events of tigecycline have been confirmed in phaseⅢ clinical trials to be gastrointestinal reactions,such as nausea,vomiting(20%-45%),pancreatitis,and elevated serum levels of bilirubin,alkaline phosphatase(ALP),alanine aminotransferase(ALT),and aspartate transaminase(AST).However,with its increasing clinical use,adverse reactions are gradually presented,in addition,some patients using tigecycline will occur liver function abnormalities and other adverse reactions,which greatly reduces the scope of tigecycline use.If serious hepatic impairment occurs,the drug should be stopped immediately and corrected in time,with the addition of drugs to protect liver function,so as not to cause acute severe drug liver injury.
万方数据
维普
